Loading data for ERNA — first visit, this takes a few seconds.

Ernexa Therapeutics Inc. (ERNA)

NasdaqCM: ERNA · Real-Time Price · USD

4.50

-0.04 (-0.88%)

At close: Sep 03, 2026, 2:12 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	3.18
Market Cap	5.25M
Revenue (ttm)	n/a
Net Income (ttm)	-12.3M
	2.56
	-0.41
	n/a
	-0.47
P/B (ttm)	1.65
P/S (ttm)	0.00
Earnings Date	Apr 15, 2022

Ask	6.15
Volume	6,023
Avg. Volume (20D)	470,858
Open	4.49
Previous Close	4.54
Day's Range	4.49 - 4.68
52-Week Range	3.18 - 71.50
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ERNA

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a li...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 29, 1991

Employees 5

Stock Exchange NasdaqCM

Ticker Symbol ERNA

Website https://www.ernexatx.com

Full Company Profile

Financial Performance

In 2025, Ernexa Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 582K. Earnings were -14.08M, a decrease of -68.38%.

Financial Statements

Earnings Surprise

Ernexa Therapeutics has released their quarterly earnings on Aug 6, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -3.4 misses estimates by -0.10, with 99.73% YoY growth.

Next Earnings Release

Ernexa Therapeutics Inc. is scheduled to release its earnings on Apr 15, 2022, after market closes.
Analysts project revenue of ... Upgrade

Why Price Moved

News

1 month ago · InvestorsHub

Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)

Ernexa Therapeutics (NASDAQ:ERNA) shares surged 30% on Wednesday after the company announced positive independent preclinical data supporting its lead cell therapy candidate, ERNA-101, for the treatme...

3 months ago · Zacks

ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know

Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.

3 months ago · 24/7 Wall St.

Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners

President Trump’s 12-word remark, “I don’t think about Americans’ financial situation, I don’t think about anybody,” hit the wires, and the reaction showed up in the forgotten corners of the market, w...

4 months ago · InvestorsHub

Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models

Ernexa Therapeutics reported new preclinical findings showing its ERNA-101 cell therapy candidate achieved complete tumor elimination and long-term survival in ovarian cancer models when combined with...

10 months ago · Associated Press Finance

BC-Most Active Stocks

YY Group Holdings Ltd. 56,330,377 0.4678

Ernexa Therapeutics Inc. (ERNA)